Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Randomized, Observer-Blind, Investigator-Initiated, Collaborative Study to Evaluate the Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults

NCT05383560 is registered in ClinicalTrials.gov with Sheba Medical Center as lead sponsor.

NCT NCT05383560
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05383560 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Randomized, Observer-Blind, Investigator-Initiated, Collaborative Study to Evaluate the Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults
Lead sponsor
Sheba Medical Center
Phase
Phase 2
Overall status
Completed
Start date
September 5, 2022
Completion date
January 31, 2024
Enrollment
179 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, covid-19 pandemic, immunogenicity, sars cov 2 infection